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MOTS  CLÉS
An  86-year-old  woman  complained  of  gradually  increasing  dyspnoea  (New  York  Heart
Association  stage  III).  Ten  years  previously  she  had  surgical  aortic  valve  replace-
ment  with  a  stented  bioprosthesis  (21  mm  Carpentier-Edwards;  Edwards  Lifesciences,
Irvine,  CA,  USA)  for  severe  symptomatic  aortic  stenosis.  At  the  same  time,  a  triple
coronary  bypass  graft  was  performed.  Five  years  after  surgery,  a permanent  pace-
maker  was  implanted.  Follow-up  transthoracic  echocardiography  demonstrated  severe
stenosis  of  the  aortic  bioprosthesis  (maximal  pressure  gradient  80  mmHg;  aortic  valve
area  0.6  cm2).  Surgery  was  contraindicated  (logistic  EuroSCORE  greater  than  20%).
The  patient  was  referred  to  our  centre  for  transcatheter  aortic  valve  implantation
(TAVI).  Preimplantation  multislice  computed  tomography  (MSCT)-angiography  conﬁrmedRemplacement
valvulaire  aortique
percutané  ;
Scanner  cardiaque  ;
Valve-in-valve
the  feasibility  of  the  transfemoral  approach,  then  a  23  mm  Edwards  SAPIEN  XT
bioprosthesis  (Edwards  Lifesciences)  was  successfully  implanted  from  a  right  trans-
femoral  approach.  Immediate  follow-up  was  unremarkable  with  no  signiﬁcant  aortic
regurgitation.  Cardiac  CT  angiography  (HD750  Discovery;  General  Electric,  Milwau-
kee,  USA)  was  performed  5  days  after  TAVI  to  evaluate  the  SAPIEN  XT  bioprosthesis
Abbreviations: MSCT, Multislice computed tomography; TAVI, Transcatheter aortic valve implantation.
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Figure 1. Cardiac multislice computed tomography (MSCT) performed 5 days after transcatheter aortic valve implantation; panels 1A and
1B: the SAPIEN XT was implanted precisely at the basal level of the degenerative bioprosthesis; panels 1C and 1D: expansion of the SAPIEN
XT was suboptimal at the basal level due to the 19 mm underlying stent; panels 1E and 1F: expansion was optimal on the aortic side of the
SAPIEN XT; panels 1G and 1H: three-dimensional volume-rendering reconstructions accurately demonstrated the close link between the two
stents.
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ositioning  and  deployment  into  the  underlying  Carpentier-
dwards  bioprosthesis.  The  Edwards-SAPIEN  XT  biopros-
hesis  was  precisely  implanted  at  the  basal  level  of  the
egenerative  bioprosthesis  (Fig.  1A  and  B).  Circularity  was
ood  but,  as  expected,  expansion  of  the  SAPIEN  XT  was  sub-
ptimal  at  the  basal  level  due  to  the  19  mm  underlying  stent
diameter  18.5  ×  18.1  mm,  measured  surface  2.67  cm2,
xpected  surface  4.15  cm2)  (Fig.  1C  and  D).  By  comparison,
n  the  aortic  side  of  the  SAPIEN  bioprosthesis,  expan-
ion  was  optimal  (Fig.  1E  and  F;  diameter  23.7  ×  22.5  mm,
easured  surface  4.19  cm2).  Three-dimensional  volume-
endering  reconstructions  accurately  demonstrated  the
lose  link  between  the  two  stents  (Fig.  1G  and  H).
TAVI  has  emerged  as  an  alternative  to  medical  treat-
ent  and  balloon  aortic  valvuloplasty  in  patients  with
ymptomatic  severe  valvular  aortic  stenosis  who  cannot  be
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eferred  for  surgery  because  of  excessive  risk  related  to
ge,  decreased  left  ventricular  function  and/or  extracar-
iac  comorbidities.  Postimplantation  evaluation  with  MSCT
ffers  a  unique  three-dimensional  acquisition  that  allows
ccurate  assessment  of  prosthesis  deployment  (circularity
nd  expansion),  and  positioning  within  the  aortic  root.  Par-
icularly  in  cases  of  valve-in-valve  implantation,  which  are
ncreasingly  frequent,  MSCT  allows  an  extremely  detailed
hree-dimensional  study  of  the  two  devices.he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
